Press releases
-
-
-
Internal link ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
-
-
-
-
-
-
-
-
-
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
-
-
Internal link ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
-
-
-
-
Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
-
Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
-
-
Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
-
-
-
Internal link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
-